What is RMGP Biopharma Investment Fund's primary investment focus?

RMGP Biopharma Investment Fund focuses on innovative early-stage biotherapeutics, primarily investing in companies operating in Israel's FutuRx incubator.

When was RMGP Biopharma Investment Fund founded?

RMGP Biopharma Investment Fund was founded in 2017.

What are the typical investment stages for RMGP Biopharma Investment Fund?

RMGP Biopharma Investment Fund typically invests in Seed and A Round stages.

Can you name some of RMGP Biopharma Investment Fund's portfolio companies?

RMGP Biopharma Investment Fund's portfolio includes companies such as BiomX, which develops microbiome therapies, and ImmPACT Bio, focused on CAR-T cell therapies.

Has RMGP Biopharma Investment Fund had any notable exits?

Yes, ImmPACT Bio, a portfolio company of RMGP Biopharma Investment Fund, was acquired by Lyell Immunopharma in October 2024. Additionally, BiomX underwent a Reverse Merger Event in November 2019 and is listed on the NYSE.

What is the sector concentration of RMGP Biopharma Investment Fund's portfolio?

RMGP Biopharma Investment Fund's portfolio is entirely concentrated in the Health Tech & Life Sciences sector, with 16 portfolio companies in this area.

Which individuals are General Partners at RMGP Biopharma Investment Fund?

Yaron Breski and Assaf Keret are General Partners at RMGP Biopharma Investment Fund.

What is the most recent investment activity by RMGP Biopharma Investment Fund?

RMGP Biopharma Investment Fund made investments in September 2022.

RMGP Biopharma Investment Fund

Venture Capital Active New York, United States Est. 2017

Visit website ↗

Last updated 2026-06-18

Portfolio

in our dataset

Rounds participated

Rounds led

Rounds' value

$210.2M

total disclosed, rounds participated

Stages

Seed, A Round

About

The RMGP Biopharma Investment Fund represents an opportunity to invest alongside industry leaders in innovative early-stage biotherapeutics through a dedicated platform. RMGP and its partners identified innovative early-stage biopharmaceutical assets as a highly attractive investment opportunity. The fund invests in early-stage biopharmaceutical solutions alongside industry leaders such as OrbiMed, J&J, and Takeda. The fund is dedicated to FutuRx's portfolio of first-in-class and best-in-class assets, and it invests exclusively in companies operating in Israel's FutuRx incubator. Based on RM Global's core investment banking capabilities, the fund will provide its portfolio companies with strategic and business development support to maximize potential return.

Portfolio · 16

Symbol Therapeutics

Modified Protein for Treatment of Autoimmune Diseases

1 round $3.0M committed Latest: 2022-09

ImmPACT Bio

CAR-T Cell Therapies for Treating Cancer

3 rounds $129.0M committed Latest: 2022-01

Skip Therapeutics

RNA-based Therapies for Genetic Disorders

1 round Latest: 2021-05

A2i Therapeutics

Novel Small-molecule Immuno-oncology Agents

1 round Latest: 2020-11

Selene Therapeutics

Epilepsy Therapy

1 round Latest: 2020-10

Circuit-Bio

Platform of Logical Gene Circuits for Cancer Immunotherapy

1 round Latest: 2020-09

JAMM Therapeutics

Systemic Lupus Erythematosus Treatment

1 round Latest: 2020-05

Nevrox

Therapeutic Small Molecule Inhibitor for Treating Neurodegenerative Disorders

1 round Latest: 2019-11

Protekt Therapeutics

PKR Inhibition for Treating Neurodegenerative Diseases

1 round Latest: 2019-11

MabTrix

Therapeutic Monoclonal Antibody for Bowel Disease

1 round Latest: 2019-06

Pi Therapeutics

Inhibitors for Cancer Treatment

1 round $19.7M committed Latest: 2019-05

Epeius Pharma

Delivery of Therapeutic Proteins into the Central Nervous System

1 round $3.5M committed Latest: 2019-02

BiomX

Microbiome Therapies for Chronic Diseases

1 round $32.0M committed Latest: 2019-02

Moya Bio

Tumor Immune Conditioning Agents

1 round $3.0M committed Latest: 2019-01

Ramino-Bio

Oral drug for treating cardio-metabolic disease and rare MSUD

1 round Latest: 2018-09

Mitoconix Bio

Therapeutics for Neurodegenerative Diseases

1 round $20.0M committed Latest: 2017-06

Investment activity

2 portfolio exits on record.

Portfolio by sector

Health Tech & Life Sciences16

Funds · 1

1 — $64M Apr 2019

Q&A

What is RMGP Biopharma Investment Fund's primary investment focus?: RMGP Biopharma Investment Fund focuses on innovative early-stage biotherapeutics, primarily investing in companies operating in Israel's FutuRx incubator.
When was RMGP Biopharma Investment Fund founded?: RMGP Biopharma Investment Fund was founded in 2017.
What are the typical investment stages for RMGP Biopharma Investment Fund?: RMGP Biopharma Investment Fund typically invests in Seed and A Round stages.
Can you name some of RMGP Biopharma Investment Fund's portfolio companies?: RMGP Biopharma Investment Fund's portfolio includes companies such as BiomX, which develops microbiome therapies, and ImmPACT Bio, focused on CAR-T cell therapies.
Has RMGP Biopharma Investment Fund had any notable exits?: Yes, ImmPACT Bio, a portfolio company of RMGP Biopharma Investment Fund, was acquired by Lyell Immunopharma in October 2024. Additionally, BiomX underwent a Reverse Merger Event in November 2019 and is listed on the NYSE.
What is the sector concentration of RMGP Biopharma Investment Fund's portfolio?: RMGP Biopharma Investment Fund's portfolio is entirely concentrated in the Health Tech & Life Sciences sector, with 16 portfolio companies in this area.
Which individuals are General Partners at RMGP Biopharma Investment Fund?: Yaron Breski and Assaf Keret are General Partners at RMGP Biopharma Investment Fund.
What is the most recent investment activity by RMGP Biopharma Investment Fund?: RMGP Biopharma Investment Fund made investments in September 2022.

Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Website	rmgpfund.com/

Identifiers & details

Founded	2017

Radar intelligence

Web history (Wayback)

Domain	rmgpfund.com